---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-228031"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2026-05-18T13:11:42+00:00"
generated_at: "2026-05-18T13:14:26.240231+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty amends merger agreement to add newly formed holding company for Ligand acquisition

## Summary
- HoldCo (XOMA Royalty Holdings Corporation) formed on May 15, 2026 and added as party to the Merger Agreement with Ligand Pharmaceuticals.
- Amendment No. 1, dated May 16, 2026, among XOMA Royalty, HoldCo, Ligand, and Merger Sub, facilitates the holding company reorganization.
- HoldCo will survive the merger as a wholly owned subsidiary of Ligand; references in the Merger Agreement are updated accordingly.
- Changes include replacing 'Company' with 'Surviving Corporation' in Sections 1.5 and 5.23, and updating the NRS statutory reference.
- Overall terms of the Merger Agreement remain unchanged; the amendment is procedural for the previously announced acquisition.

## SEC filing metadata
- accession: 0001193125-26-228031
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2026-05-18T13:11:42+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312526228031/0001193125-26-228031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312526228031/d130820d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-228031
- JSON: https://secwatch.observer/filing/0001193125-26-228031.json
- Plain text: https://secwatch.observer/filing/0001193125-26-228031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.